Insulet (NASDAQ:PODD) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

PODD has been the subject of a number of other research reports. Jefferies Group restated a “buy” rating and set a $58.00 price objective (up previously from $48.00) on shares of Insulet in a research report on Wednesday, August 9th. Northland Securities restated a “buy” rating on shares of Insulet in a research report on Friday, August 4th. Oppenheimer set a $55.00 price objective on shares of Insulet and gave the stock a “hold” rating in a research report on Friday, August 4th. Barclays upped their price objective on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. Finally, Cowen restated an “outperform” rating and set a $63.00 price objective (up previously from $52.00) on shares of Insulet in a research report on Friday, August 4th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Insulet presently has an average rating of “Buy” and a consensus target price of $61.07.

Insulet (PODD) traded down $1.05 during mid-day trading on Friday, reaching $70.68. 457,708 shares of the company traded hands, compared to its average volume of 983,254. Insulet has a 1 year low of $32.19 and a 1 year high of $72.99. The company has a quick ratio of 4.42, a current ratio of 4.88 and a debt-to-equity ratio of 4.65.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The firm had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same quarter in the prior year, the firm earned ($0.05) EPS. Insulet’s revenue for the quarter was up 28.4% on a year-over-year basis. equities research analysts forecast that Insulet will post -0.42 earnings per share for the current fiscal year.

In related news, Director James C. Mullen purchased 2,500 shares of the stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Granite Investment Partners LLC grew its stake in shares of Insulet by 0.4% during the 2nd quarter. Granite Investment Partners LLC now owns 19,502 shares of the medical instruments supplier’s stock worth $1,001,000 after purchasing an additional 76 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Insulet by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,746 shares of the medical instruments supplier’s stock worth $2,296,000 after purchasing an additional 198 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Insulet by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after purchasing an additional 235 shares during the period. Legal & General Group Plc grew its stake in shares of Insulet by 1.9% during the 2nd quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock worth $1,034,000 after purchasing an additional 376 shares during the period. Finally, Amalgamated Bank grew its stake in shares of Insulet by 5.7% during the 2nd quarter. Amalgamated Bank now owns 7,476 shares of the medical instruments supplier’s stock worth $384,000 after purchasing an additional 406 shares during the period.

WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/12/02/insulet-podd-downgraded-to-hold-at-bidaskclub.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.